| Publication |
Sentence |
Publish Date |
Extraction Date |
Species |
| E Rask, T Olsson, S Söderberg, J j Holst Jj, A Tura, G Pacini, B Ahré. Insulin secretion and incretin hormones after oral glucose in non-obese subjects with impaired glucose tolerance. Metabolism: clinical and experimental. vol 53. issue 5. 2004-07-08. PMID:15131768. |
in this study, we sought to establish the interrelation between insulin secretion and insulin sensitivity after oral glucose in non-obese subjects with igt and we also examined this interrelation in relation to the 2 main incretins, glucagon-like peptide (glp-1) and gastric inhibitory polypeptide (gip). |
2004-07-08 |
2023-08-12 |
human |
| E Rask, T Olsson, S Söderberg, J j Holst Jj, A Tura, G Pacini, B Ahré. Insulin secretion and incretin hormones after oral glucose in non-obese subjects with impaired glucose tolerance. Metabolism: clinical and experimental. vol 53. issue 5. 2004-07-08. PMID:15131768. |
to that end, 13 women with igt and 17 women with normal glucose tolerance (ngt) underwent an oral glucose tolerance test (ogtt) with measurements of glucose, insulin, c-peptide, glp-1, and gip. |
2004-07-08 |
2023-08-12 |
human |
| J Lovshin, D J Drucke. Synthesis, secretion and biological actions of the glucagon-like peptides. Pediatric diabetes. vol 1. issue 1. 2004-06-30. PMID:15016242. |
glp-1 regulates blood glucose via actions on gastric emptying and islet hormones, including the regulation of insulin, glucagon, and somatostatin secretion. |
2004-06-30 |
2023-08-12 |
human |
| J Lovshin, D J Drucke. Synthesis, secretion and biological actions of the glucagon-like peptides. Pediatric diabetes. vol 1. issue 1. 2004-06-30. PMID:15016242. |
glp-1 action is essential for beta-cell function, because the disruption of glp-1 signaling results in reduced insulin secretion, decreased islet cyclic adenosine monophosphate, and abnormal intracellular calcium oscillations. |
2004-06-30 |
2023-08-12 |
human |
| Kyle W Sloop, Julia Xiao-Chun Cao, Angela M Siesky, Hong Yan Zhang, Diane M Bodenmiller, Amy L Cox, Steven J Jacobs, Julie S Moyers, Rebecca A Owens, Aaron D Showalter, Martin B Brenner, Achim Raap, Jesper Gromada, Brian R Berridge, David K B Monteith, Niels Porksen, Robert A McKay, Brett P Monia, Sanjay Bhanot, Lynnetta M Watts, M Dodson Michae. Hepatic and glucagon-like peptide-1-mediated reversal of diabetes by glucagon receptor antisense oligonucleotide inhibitors. The Journal of clinical investigation. vol 113. issue 11. 2004-06-29. PMID:15173883. |
importantly, in addition to decreasing expression of camp-regulated genes in liver and preventing glucagon-mediated hepatic glucose production, gcgr inhibition increased serum concentrations of active glucagon-like peptide-1 (glp-1) and insulin levels in pancreatic islets. |
2004-06-29 |
2023-08-12 |
Not clear |
| James F List, Joel F Habene. Glucagon-like peptide 1 agonists and the development and growth of pancreatic beta-cells. American journal of physiology. Endocrinology and metabolism. vol 286. issue 6. 2004-06-25. PMID:15140754. |
glucagon-like peptide 1 (glp-1) is an intestine-derived insulinotropic hormone that stimulates glucose-dependent insulin production and secretion from pancreatic beta-cells. |
2004-06-25 |
2023-08-12 |
Not clear |
| David A D'Alessio, Torsten P Vah. Glucagon-like peptide 1: evolution of an incretin into a treatment for diabetes. American journal of physiology. Endocrinology and metabolism. vol 286. issue 6. 2004-06-25. PMID:15140755. |
glp-1 is insulinotropic and plays a role in the incretin effect, the augmented insulin response observed when glucose is absorbed through the gut. |
2004-06-25 |
2023-08-12 |
Not clear |
| David A D'Alessio, Torsten P Vah. Glucagon-like peptide 1: evolution of an incretin into a treatment for diabetes. American journal of physiology. Endocrinology and metabolism. vol 286. issue 6. 2004-06-25. PMID:15140755. |
these effects, in addition to the stimulation of insulin secretion, suggest a broad role for glp-1 as a mediator of postprandial glucose homeostasis. |
2004-06-25 |
2023-08-12 |
Not clear |
| David A D'Alessio, Torsten P Vah. Glucagon-like peptide 1: evolution of an incretin into a treatment for diabetes. American journal of physiology. Endocrinology and metabolism. vol 286. issue 6. 2004-06-25. PMID:15140755. |
whereas other insulinotropic gastrointestinal hormones are relatively ineffective in stimulating insulin secretion in persons with type 2 diabetes, glp-1 retains this action and is very effective in lowering blood glucose levels in these patients. |
2004-06-25 |
2023-08-12 |
Not clear |
| M Bayés, X Rabasseda, J R Prou. Gateways to clinical trials. Methods and findings in experimental and clinical pharmacology. vol 25. issue 8. 2004-06-21. PMID:14671684. |
this issue focuses on the following selection of drugs: 3,4-dap; adefovir dipivoxil, adl-10-0101, alefacept, alemtuzumab, alosetron hydrochloride, alt-711, aprepitant, atazanavir sulfate, atlizumab, atvogen; bortezomib; cetp vaccine, clevudine, crofelemer; dac:glp-1, darbepoetin alfa, decitabine, drotrecogin alfa (activated), dx-9065a; e-7010, edodekin alfa, emivirine, emtricitabine, entecavir, erlosamide, erlotinib hydrochloride, everolimus, exenatide; fondaparinux sodium, frovatriptan, fulvestrant; gemtuzumab ozogamicin, gestodene; homoharringtonine, human insulin; imatinib mesylate, indiplon, indium 111 (111in) ibritumomab tiuxetan, inhaled insulin, insulin detemir, insulin glargine, ivabradine hydrochloride; lanthanum carbonate, lapatinib, las-34475, levetiracetam, liraglutide, lumiracoxib; maxacalcitol, melagatran, micafungin sodium; natalizumab, nsc-640488; oblimersen sodium; parecoxib sodium, peg-filgrastim, peginterferon alfa-2(a), peginterferon alfa-2b, pexelizumab, pimecrolimus, pleconaril, pramlintide acetate, pregabalin, prucalopride; rahf-pfm, ranelic acid distrontium salt, ranolazine, rdna insulin, recombinant human soluble thrombomodulin, rhgm-csf, roxifiban acetate, rsd-1235, rubitecan, ruboxistaurin mesilate hydrate; sc-51, squalamine; tegaserod maleate, telbivudine, tesaglitazar, testosterone gel, tezosentan disodium, tipranavir; vatalanib succinate; ximelagatran; yttrium 90 (90y) ibritumomab tiuxetan; zoledronic acid monohydrate. |
2004-06-21 |
2023-08-12 |
human |
| Harald Stingl, Michael Rode. [Future targets in the treatment of type 2 diabetes]. Wiener klinische Wochenschrift. vol 116. issue 7-8. 2004-06-17. PMID:15143860. |
agonists of glucagon-like-peptide 1 (glp-1) and antagonists of dipeptidylpeptidase iv, which inactivates glp-1, stimulate glucose-dependent insulin secretion, improve hyperglycemia and are already tested in clinical trials. |
2004-06-17 |
2023-08-12 |
Not clear |
| Angela Bulotta, Riccardo Perfetti, Hongxiang Hui, László G Boro. GLP-1 stimulates glucose-derived de novo fatty acid synthesis and chain elongation during cell differentiation and insulin release. Journal of lipid research. vol 44. issue 8. 2004-06-14. PMID:12777469. |
glp-1 stimulates glucose-derived de novo fatty acid synthesis and chain elongation during cell differentiation and insulin release. |
2004-06-14 |
2023-08-12 |
human |
| Juris J Meier, Michael A Nauck, Daniel Kranz, Jens J Holst, Carolyn F Deacon, Dirk Gaeckler, Wolfgang E Schmidt, Baptist Gallwit. Secretion, degradation, and elimination of glucagon-like peptide 1 and gastric inhibitory polypeptide in patients with chronic renal insufficiency and healthy control subjects. Diabetes. vol 53. issue 3. 2004-06-08. PMID:14988249. |
venous blood samples were drawn for the determination of glucose (glucose oxidase), insulin, c-peptide, glp-1 (total and intact), and gip (total and intact; specific immunoassays). |
2004-06-08 |
2023-08-12 |
human |
| A Acitores, N González, V Sancho, I Valverde, M L Villanueva-Peñacarrill. Cell signalling of glucagon-like peptide-1 action in rat skeletal muscle. The Journal of endocrinology. vol 180. issue 3. 2004-05-27. PMID:15012593. |
we first explored the effect of glp-1, compared with that of insulin, on the activation of pi3k, pkb, p70s6 kinase (p70s6k) and p44/42 mitogen-activated protein kinases (mapks) and the action of specific inhibitors of these kinases on the insulin- and glp-1-induced increment in glycogen synthase a activity. |
2004-05-27 |
2023-08-12 |
rat |
| A Acitores, N González, V Sancho, I Valverde, M L Villanueva-Peñacarrill. Cell signalling of glucagon-like peptide-1 action in rat skeletal muscle. The Journal of endocrinology. vol 180. issue 3. 2004-05-27. PMID:15012593. |
the study showed that glp-1, like insulin, activated pi3k/pkb, p70s6k and p44/42. |
2004-05-27 |
2023-08-12 |
rat |
| A Acitores, N González, V Sancho, I Valverde, M L Villanueva-Peñacarrill. Cell signalling of glucagon-like peptide-1 action in rat skeletal muscle. The Journal of endocrinology. vol 180. issue 3. 2004-05-27. PMID:15012593. |
wortmannin (a pi3k inhibitor) reduced the stimulatory action of insulin on glycogen synthase a activity and blocked that of glp-1, rapamycin (a 70s6k inhibitor) did not affect the action of glp-1 but abolished that of insulin, pd98059 (mapk inhibitor) was ineffective on insulin but blocked the action of glp-1, okadaic acid (a pp-2a inhibitor) and tumour necrosis factor-alpha (a pp-1 inhibitor) were both ineffective on glp-1 but abolished the action of insulin, and ro 31-8220 (an inhibitor of some pkc isoforms) reduced the effect of glp-1 while completely preventing that of insulin. |
2004-05-27 |
2023-08-12 |
rat |
| A Acitores, N González, V Sancho, I Valverde, M L Villanueva-Peñacarrill. Cell signalling of glucagon-like peptide-1 action in rat skeletal muscle. The Journal of endocrinology. vol 180. issue 3. 2004-05-27. PMID:15012593. |
it was concluded that activation of pi3k/pkb and mapks is required for the glp-1-induced increment in glycogen synthase a activity, while pkc, although apparently participating, does not seem to play an essential role; unlike in insulin signaling, p70s6k, pp-1 and pp-2a do not seem to be needed in the action of glp-1 upon glycogen synthase a activity in rat muscle. |
2004-05-27 |
2023-08-12 |
rat |
| Bo Ahrén, Jens J Holst, Andrea Mar. Characterization of GLP-1 effects on beta-cell function after meal ingestion in humans. Diabetes care. vol 26. issue 10. 2004-05-20. PMID:14514592. |
glucagon-like peptide 1 (glp-1) is an incretin that augments insulin secretion after meal intake and is developed for treatment of type 2 diabetes. |
2004-05-20 |
2023-08-12 |
Not clear |
| Brian D Green, Victor A Gault, Mark H Mooney, Nigel Irwin, Patrick Harriott, Brett Greer, Cliff J Bailey, Finbarr P M O'Harte, Peter R Flat. Degradation, receptor binding, insulin secreting and antihyperglycaemic actions of palmitate-derivatised native and Ala8-substituted GLP-1 analogues. Biological chemistry. vol 385. issue 2. 2004-05-19. PMID:15101559. |
degradation, receptor binding, insulin secreting and antihyperglycaemic actions of palmitate-derivatised native and ala8-substituted glp-1 analogues. |
2004-05-19 |
2023-08-12 |
mouse |
| Brian D Green, Victor A Gault, Mark H Mooney, Nigel Irwin, Patrick Harriott, Brett Greer, Cliff J Bailey, Finbarr P M O'Harte, Peter R Flat. Degradation, receptor binding, insulin secreting and antihyperglycaemic actions of palmitate-derivatised native and Ala8-substituted GLP-1 analogues. Biological chemistry. vol 385. issue 2. 2004-05-19. PMID:15101559. |
the hormone glucagon-like peptide-1(7-36)amide (glp-1) is released in response to ingested nutrients and acts to promote glucose-dependent insulin secretion ensuring efficient postprandial glucose homeostasis. |
2004-05-19 |
2023-08-12 |
mouse |